Fig. 2: Morusinol exerts antitumor effects by targeting FUT8.

A Coomassie bule of the gel after SDS-PAGE of the potential Morusinol binding proteins. Specific bands were excised and analyzed through Liquid Chromatograph Mass Spectrometer (LC-MS). The red arrow indicates gel band unique to Morusinol. The unique gel band was sent for LC-MS protein detection. B Protein-protein interaction (PPI) network derived from the results of differential protein banding analysis using LC-MS. C The process of drug target protein screening. D Single peptide-based protein identification of FUT8. E The survival curve of the DLBCL patients based on FUT8 expression in the GSE10846 and GSE32918. F The expression of FUT8 in a variety of malignancies from the GEPIA database. G The expression of FUT8 in DLBCL cells based on individual tumor stages. H, I The results of GO and KEGG mapping. J C-index values of NCCN-IPI plus FUT8 model and NCCN-IPI model in multiple regression analysis. K The ability of Morusinol to bind to the FUT8 ligand-binding domain by molecular docking. L Cellular thermal shift assay showing FUT8 target engagement by Morusinol in DLBCL cells. DLBCL cells were incubated with Morusinol for 12 h, and cellular thermal shift assay was carried out. M The expression level of FUT8 was detected by qPCR. N CCK-8 assay was performed to detect the cell proliferation after FUT8 interference. O SU-DHL-8, SU-DHL-2, and Farage cells were transfected with siFUT8-3068 for 48 h, double stained with 7-AAD and Annexin V-PE, and analyzed by flow cytometry. Percentages of apoptotic cells are shown in the statistical graph. P SU-DHL-8, SU-DHL-2, and Farage cells were transfected with siFUT8-3068 for 48 h, stained with PI, and analyzed by flow cytometry. Percentages of G0/G1, S, and G2/M phases in the cell cycle are shown in the statistical graph. All data are shown as the means ± SD based on triplicate measures. *P < 0.05, **P < 0.01 and ***P < 0.001.